MiR-126: a novel route for natalizumab action?

Abstract

Background:

MicroRNAs (miRNAs) have emerged as a family of post-transcriptional regulators of gene expression that mediate diverse aspects of immunity. MiRNA dysregulation has been found in multiple sclerosis (MS), reflecting the growing need to identify disease-specific miRNA expression signatures. Our previous low-density array studies reveal differential miR-126 expression in the CD4⁺T cells of untreated relapsing–remitting MS (RRMS) patients. Here, we investigated miR-126 expression in natalizumab-treated patients.

Methods:

We isolated CD4⁺ T cells from untreated (n = 12) and natalizumab-treated MS patients (n = 24), and from healthy volunteers (n = 12). We analyzed the expression of miRNAs and potential targets by real time reverse transcription polymerase chain reaction (RT-PCR). We assessed specific inhibition of miR-126, in vitro.

Results:

MiR-126 was down-regulated in cells of patients under natalizumab treatment and up-regulated during relapse, supporting a regulatory role in MS immunopathogenesis. MiR-126 expression correlated with the expression of POU2AF1, a regulator of Spi-B that binds to the promoter/enhancer sequences of JC virus (JCV), the pathogen of progressive multifocal leukoencephalopathy (PML), a rare complication of natalizumab treatment. The same trend was found for Spi-B. Strong up-regulation of both genes appeared to be treatment duration-dependent. Specific inhibition experiments supported the link between the expression of miR-126 and POU2AF1/Spi-B.

Conclusions:

Our findings provided deeper insight into the mode of action of natalizumab, with possible implications for understanding both the effects of natalizumab on MS activity and its specific adverse event profile.

Keywords

Adverse events mechanism of action miR-126 miRNA multiple sclerosis natalizumab progressive multifocal leukoencephalopathy

Get full access to this article

View all access options for this article.

References

Compston

Coles

. Multiple sclerosis. Lancet 2008; 372: 1502–1517.

Huynh

Casaccia

. Epigenetic mechanisms in multiple sclerosis: Implications for pathogenesis and treatment. Lancet Neurol 2013; 12: 195–206.

Fabian

Sonenberg

Filipowicz

. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79: 351–379.

Bartel

. MicroRNAs: Genomics, biogenesis, mechanism and function. Cell 2004; 116: 281–297.

Lindsay

. MicroRNAs and the immune response. Trends Immunol 2008; 29: 343–351.

Farazi

Hoell

Morozov

. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774: 1–20.

De Faria

Jr Moore

Kennedy

. MicroRNA Dysregulation in multiple sclerosis. Frontiers Genet 2013; 3: 1–6.

Otaegui

Baranzini

Armananzas

. Differential microRNA expression in PBMC from multiple sclerosis patients. PLoS One 2009; 4: e6309.

Liu

Kang

. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nature immunol 2009; 10: 1252–1259.

10.

Sondergaard

Hesse

Krakauer

. Differential microRNA expression in blood in multiple sclerosis. Mult Scler 2013 Dec;19(14):1849–1857.

11.

Lindberg

Hoffmann

Mehling

. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing–remitting multiple sclerosis patients. Europ J Immunol 2010; 40: 888–898.

12.

Sievers

Meira

Hoffmann

. Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects. Clin Immunol 2012; 144: 70–79.

13.

Hutchinson

. Natalizumab: A new treatment for relapsing–remitting multiple sclerosis. Ther Clin Risk Manag 2007; 3: 259–268.

14.

Kappos

O’Connor

Polman

. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol 2013; 260: 1388–1395.

15.

Bloomgren

Richman

Hotermans

. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New Engl J Med 2012; 366: 1870–1880.

16.

Lindberg

Achtnichts

Hoffmann

. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194: 153–164.

17.

Mattes

Collison

Plank

. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci USA 2009; 106: 18704–18709.

18.

Bartholdy

Du Roure

Bordon

. The Ets factor Spi-B is a direct critical target of the coactivator OBF-1. Proc Natl Acad Sci USA 2006; 103: 11665–11670.

19.

Marshall

Dunham

Major

. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol 2010; 91: 3042–3052.

20.

Ban

Booth

Heard

. Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. J Neuroimmunol 2006; 179: 108–116.

21.

Waschbisch

Atiya

Linker

. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing–remitting multiple sclerosis. PLoS One 2011; 6: e24604.

22.

Hecker

Michael

Madhan

Thamilarasan

Dirk

Koczan

. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Molec Sci 2013; 14: 16087–16110.

23.

Harris

Yamakuchi

Kondo

. Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells. Arterioscler Thromb Vasc Biol 2010; 30: 1990–1997.

24.

Moisan

Grenningloh

Bettelli

. Ets-1 is a negative regulator of Th17 differentiation. J Exp Med 2007; 204: 2825–2835.

25.

Strubin

Newell

Matthias

. OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins. Cell 1995; 80: 497–506.

26.

Zwilling

Dieckmann

Pfisterer

. Inducible expression and phosphorylation of coactivator BOB.1/OBF.1 in T cells. Science 1997; 277: 221–225.

27.

Brunner

Sindrilaru

Girkontaite

. BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responses. Embo J 2007; 26: 3191–3202.

28.

Yosef

Shalek

Gaublomme

. Dynamic regulatory network controlling TH17 cell differentiation. Nature 2013; 496: 461–468.

29.

Cobb

. The Ets protein Spi-B is expressed exclusively in B cells and T cells during development. J Exp Med 1996; 184: 203–214.

30.

Dorries

Sbiera

Drews

. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol 2003; 9: 81–87.

31.

Monaco

Atwood

Gravell

. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes and tonsillar stromal cells: Implications for viral latency. J Virol 1996; 70: 7004–7012.

32.

Wei

Liu

Atwood

. JC virus binds to primary human glial cells, tonsillar stromal cells, and B lymphocytes, but not to T lymphocytes. J Neurovirol 2000; 6: 127–136.

33.

Chapagain

Nerurkar

. Human polyomavirus JC (JCV) infection of human B lymphocytes: A possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 2010; 202: 184–191.

34.

Mittelbrunn

Gutierrez-Vazquez

Villarroya-Beltri

. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2011; 2: 282–291.

35.

Valadi

Ekstrom

Bossios

. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654–659.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.55 MB